Literature DB >> 34147078

In vivo confocal microscopy assessment of meibomian glands microstructure in patients with Graves' orbitopathy.

Shengnan Cheng1, Yueqi Yu1, Jin Chen1, Lin Ye2, Xinghua Wang3, Fagang Jiang4.   

Abstract

BACKGROUND: To evaluate microstructural changes in the meibomian glands (MGs) in patients with active and inactive Graves' orbitopathy (GO), using in vivo confocal microscopy (IVCM), and to investigate the correlations between clinical and confocal findings.
METHODS: Forty patients (80 eyes) with GO (34 eyes with active GO, 46 eyes with inactive GO), and 31 age- and sex-matched control participants (62 eyes) were enrolled consecutively. A researcher recorded the clinical activity score (CAS) for each patient. A complete ophthalmic examination was then performed, including external eye, ocular surface and MGs. IVCM of the MGs was performed to determine the MG acinar density (MAD), MG longest and shortest diameters (MALD and MASD), MG orifice area (MOA), MG acinar irregularity (MAI), meibum secretion reflectivity (MSR), acinar wall inhomogeneity (AWI), acinar periglandular interstices inhomogeneity (API), and severity of MG fibrosis (MF).
RESULTS: All confocal microscopy assessments of MGs significantly differed among groups (all P = 0.000). Compared to controls, GO groups showed lower MOA (1985.82 ± 1325.30 μm2 in active GO and 2021.59 ± 1367.45 μm2 in inactive GO vs. 3896.63 ± 891.90 μm2 in controls, all P = 0.000) and MAD (87.21 ± 32.69 /mm2 in active GO and 80.72 ± 35.54 /mm2 in inactive GO vs. 114.69 ± 34.90 /mm2 in controls, P = 0.001 and 0.000, respectively); greater MALD (118.11 ± 30.23 μm in active GO and 120.58 ± 27.64 μm in inactive GO vs. 58.68 ± 20.28 μm in controls, all P = 0.000) and MASD (44.77 ± 19.16 μm in active GO and 46.02 ± 20.70 μm in inactive GO vs. 27.80 ± 9.90 μm in controls, all P = 0.000); and higher degrees of MAI, MSR, and MF (all P<0.05). Eyes with active GO had higher degrees of MAI (P = 0.015), AWI (P = 0.000), and API (P = 0.000), while eyes with inactive GO had higher degrees of MSR (P = 0.000) and MF (P = 0.017). In GO groups, AWI and API were positively correlated with CAS (r = 0.640, P = 0.000; r = 0.683, P = 0.000, respectively), and MF was negatively correlated with CAS (r = - 0.228, P = 0.042).
CONCLUSIONS: IVCM effectively revealed microstructural changes of MGs in eyes with GO and provided strong in vivo evidence for the roles of obstruction and inflammation in the ocular surface disease process. Furthermore, it revealed discernible patterns of MG abnormalities in eyes with active GO and inactive GO, which are not easily distinguishable by typical clinical examinations.

Entities:  

Keywords:  Graves’ orbitopathy; In vivo confocal microscopy; Meibomian glands; Microstructure

Year:  2021        PMID: 34147078     DOI: 10.1186/s12886-021-02024-z

Source DB:  PubMed          Journal:  BMC Ophthalmol        ISSN: 1471-2415            Impact factor:   2.209


  46 in total

Review 1.  Ocular surface effects of thyroid disease.

Authors:  Jason A Sokol; Gary N Foulks; Ali Haider; William R Nunery
Journal:  Ocul Surf       Date:  2010-01       Impact factor: 5.033

Review 2.  Graves upper eyelid retraction.

Authors:  Antonio Augusto Velasco Cruz; Sara F T Ribeiro; Denny M Garcia; Patricia Mitiko Akaishi; Carolina T Pinto
Journal:  Surv Ophthalmol       Date:  2013 Jan-Feb       Impact factor: 6.048

3.  Ocular surface and dry eye in Graves' disease.

Authors:  Canan Gürdal; Ozge Saraç; Ipek Genç; Hale Kırımlıoğlu; Tamer Takmaz; Izzet Can
Journal:  Curr Eye Res       Date:  2011-01       Impact factor: 2.424

4.  Long-term follow-up of Graves ophthalmopathy in an incidence cohort.

Authors:  G B Bartley; V Fatourechi; E F Kadrmas; S J Jacobsen; D M Ilstrup; J A Garrity; C A Gorman
Journal:  Ophthalmology       Date:  1996-06       Impact factor: 12.079

5.  Dry eye syndrome in thyroid-associated ophthalmopathy: lacrimal expression of TSH receptor suggests involvement of TSHR-specific autoantibodies.

Authors:  Anja K Eckstein; Andreas Finkenrath; Arnd Heiligenhaus; Katrin Renzing-Köhler; Joachim Esser; Carsten Krüger; Beate Quadbeck; Klaus-Peter Steuhl; Robert K Gieseler
Journal:  Acta Ophthalmol Scand       Date:  2004-06

6.  Observation of Corneal Langerhans Cells by In Vivo Confocal Microscopy in Thyroid-Associated Ophthalmopathy.

Authors:  Lian-Qun Wu; Jin-Wei Cheng; Ji-Ping Cai; Qi-Hua Le; Xiao-Ye Ma; Lian-Di Gao; Rui-Li Wei
Journal:  Curr Eye Res       Date:  2016-01-06       Impact factor: 2.424

7.  Clinical features of Graves' ophthalmopathy in an incidence cohort.

Authors:  G B Bartley; V Fatourechi; E F Kadrmas; S J Jacobsen; D M Ilstrup; J A Garrity; C A Gorman
Journal:  Am J Ophthalmol       Date:  1996-03       Impact factor: 5.258

8.  Does Graves' Orbitopathy Ever Disappear? Answers to an Old Question.

Authors:  Elena Sabini; Marenza Leo; Barbara Mazzi; Roberto Rocchi; Francesco Latrofa; Marco Nardi; Paolo Vitti; Claudio Marcocci; Michele Marinò
Journal:  Eur Thyroid J       Date:  2017-06-26

9.  Association of T and B Cells Infiltrating Orbital Tissues With Clinical Features of Graves Orbitopathy.

Authors:  Giovanna Rotondo Dottore; Liborio Torregrossa; Patrizio Caturegli; Ilaria Ionni; Angela Sframeli; Elena Sabini; Francesca Menconi; Paolo Piaggi; Stefano Sellari-Franceschini; Marco Nardi; Francesco Latrofa; Paolo Vitti; Claudio Marcocci; Fulvio Basolo; Michele Marinò
Journal:  JAMA Ophthalmol       Date:  2018-06-01       Impact factor: 7.389

Review 10.  Update on thyroid-associated Ophthalmopathy with a special emphasis on the ocular surface.

Authors:  Priscila Novaes; Ana Beatriz Diniz Grisolia; Terry J Smith
Journal:  Clin Diabetes Endocrinol       Date:  2016-11-16
View more
  1 in total

Review 1.  In Vivo Confocal Microscopy in Different Types of Dry Eye and Meibomian Gland Dysfunction.

Authors:  Ralene Sim; Kenneth Yong; Yu-Chi Liu; Louis Tong
Journal:  J Clin Med       Date:  2022-04-22       Impact factor: 4.964

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.